Trial Profile
A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs SIILPCV10 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- 13 Dec 2019 Results published in the Vaccine
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 13 Sep 2016 Planned End Date changed from 1 May 2016 to 1 Oct 2016.